Our review highlights IL-13Rα2 and EphA2 as clinically relevant biomarkers for these cancer subtypes, noting their minimal expression in normal tissue, which underscores their potential as targets for CAR T-cell therapy. This evidence concerns the gene EPHA2 and cancer.